Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979

Publications

Glajchen, M., and J. W. Moul. “Teleconferencing as a method of educating men about managing advanced prostate cancer and pain.” Journal of Psychosocial Oncology 14, no. 2 (December 1, 1996): 73–87. https://doi.org/10.1300/J077V14N02_05.

Full Text

Heidenberg, H. B., J. J. Bauer, D. G. McLeod, J. W. Moul, and S. Srivastava. “The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?.” Urology 48, no. 6 (December 1996): 971–79. https://doi.org/10.1016/s0090-4295(96)00365-2.

Full Text

Bauer, J. J., D. G. Mcleod, and J. W. Moul. “Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994..” Mil Med 161, no. 11 (November 1996): 646–53.

Scholars@Duke

Bauer, J. J., I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, S. Srivastava, and J. W. Moul. “Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer..” J Urol 156, no. 4 (October 1996): 1511–16.

Scholars@Duke

Bettencourt, M. C., J. J. Bauer, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, and J. W. Moul. “Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy..” J Urol 156, no. 3 (September 1996): 1064–68.

Scholars@Duke

Moul, J. W., and A. Heidenreich. “Prognostic factors in low-stage nonseminomatous testicular cancer..” Oncology (Williston Park) 10, no. 9 (September 1996): 1359–74.

Scholars@Duke

Morgan, T. O., S. J. Jacobsen, W. F. McCarthy, D. J. Jacobson, D. G. McLeod, and J. W. Moul. “Age-specific reference ranges for serum prostate-specific antigen in black men..” N Engl J Med 335, no. 5 (August 1, 1996): 304–10. https://doi.org/10.1056/NEJM199608013350502.

Full Text

Moul, J. W., M. C. Bettencourt, I. A. Sesterhenn, F. K. Mostofi, D. G. McLeod, S. Srivastava, and J. J. Bauer. “Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer..” Surgery 120, no. 2 (August 1996): 159–66. https://doi.org/10.1016/s0039-6060(96)80283-2.

Full Text

Styler, M. J., P. Crilley, J. Biggs, J. Moul, E. Copelan, D. Topolsky, B. Avalos, et al. “Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis..” Bone Marrow Transplant 18, no. 1 (July 1996): 171–76.

Scholars@Duke

Moul, J. W., T. H. Douglas, W. F. McCarthy, and D. G. McLeod. “Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting..” J Urol 155, no. 5 (May 1996): 1667–73.

Scholars@Duke

Pages